Maintenance vs. incurrence covenants, the financial tests that trip them, and exactly what happens when a company breaches — calibrated for direct lending interviews.
Covenants are contractual promises a borrower makes to its lenders. Break the promise and you have a default — not necessarily a missed payment, but a breach of agreed operating parameters that gives lenders the right to accelerate the loan. Understanding the difference between maintenance and incurrence covenants is the single most important distinction in leveraged credit.
| Type | When Tested | Who Uses | Consequence of Breach | Examples |
|---|---|---|---|---|
| Maintenance | Quarterly, regardless of borrower actions | Bank market, direct lending (unitranche) | Immediate event of default; waiver required | Max Leverage, Min Interest Coverage, Min Liquidity |
| Incurrence | Only when borrower takes a specific action | Institutional TLB, high yield bonds | Action is blocked if test not satisfied | Debt incurrence basket, restricted payments test, asset sale proceeds |
The practical difference is enormous. A maintenance covenant is an ongoing heartbeat check: every quarter, the borrower certifies it is within the agreed bands. If the business underperforms, lenders learn about it early and can intervene. An incurrence covenant only activates when the company tries to do something — take on more debt, pay a dividend, sell an asset. If the company does nothing, the test is never run, even if the balance sheet has quietly deteriorated past the threshold.
Direct lenders and bank revolving credit facilities typically include a suite of maintenance covenants. These are the four most common, with worked examples calibrated to what you will see in the market today.
The most universal covenant. Expresses total net debt (or gross debt, depending on the agreement) as a multiple of Adjusted EBITDA. Step-downs are common — the covenant tightens over time to reflect the expected deleveraging trajectory.
| Quarter | Max Leverage Covenant | Actual Leverage | Headroom | Status |
|---|---|---|---|---|
| Q1 2025 | 5.75x | 5.30x | 0.45x | Compliant |
| Q2 2025 | 5.50x | 5.30x | 0.20x | Tight — watch list |
| Q3 2025 | 5.50x | 5.60x | (0.10x) | Breach — waiver needed |
| Q4 2025 | 5.25x | 5.10x | 0.15x | Compliant (post-cure) |
At Q3 2025 the company breaches. Total debt is $440M, LTM Adjusted EBITDA is $78.6M: leverage = 5.60x against a 5.50x maximum. The covenant is tripped by $7.8M of EBITDA (shortfall = ($5.60x - $5.50x) × $78.6M / $5.60x ≈ $1.4M in incremental EBITDA needed). A waiver request goes to the lender group within 5 business days of quarter-end.
When a borrower trips maximum leverage, the typical resolution path involves three elements: a fee (25–50bps on outstanding balance), a covenant reset at a wider level with tighter step-downs, and in some cases an equity cure. If the step-down is the problem — the covenant tightened faster than the business improved — the amendment will often flatten the schedule for 2–4 quarters.
Expressed as EBITDA divided by cash interest expense. Lenders care about this because it tells them whether the business generates enough operating income to service its debt each period, before any principal or capex obligations.
Example: Company has LTM Adjusted EBITDA of $86M. Cash interest expense (first lien $400M at S+450, second lien $150M at S+875, using SOFR of 5.30%) works out to approximately $40M. Coverage = $86M / $40M = 2.15x against a 2.00x minimum covenant. Headroom is just 0.15x — a 7% EBITDA decline from here trips the covenant. A prudent analyst puts this on the watch list.
Common in revolving credit facilities and direct lending deals where near-term liquidity risk is elevated. Defined as unrestricted cash plus availability under the revolving credit facility. The floor is typically set at 1–2 months of operating expenses or a fixed dollar amount.
| Component | Amount ($M) |
|---|---|
| Unrestricted Cash | $12.4 |
| Revolving Credit Facility — Commitment | $50.0 |
| Less: Outstanding Draws | ($22.5) |
| Less: Letters of Credit | ($4.0) |
| Revolver Availability | $23.5 |
| Total Liquidity | $35.9 |
At $35.9M, the company is $10.9M above the $25M minimum. But the revolver is 45% drawn and the company is burning cash — if it draws another $11M and cash drops $1M, liquidity falls to $24.9M: a breach. Lenders will flag revolver utilization above 40–50% as a leading indicator to monitor.
A maximum annual capex basket, typically $40–75M for a mid-market company, with a common carryforward provision (often 50% of unused allowance from the prior year, capped at one year). This prevents the company from using capex-heavy growth initiatives to burn lender-preferred free cash flow without consent.
Example: $50M annual capex covenant with 50% carryforward. Company spends $38M in Year 1 — unused allowance is $12M, of which $6M (50%) carries into Year 2. Year 2 limit becomes $56M. If the company spends more than $56M in Year 2 without an amendment, it is in breach.
In the broadly syndicated term loan B (TLB) market, maintenance covenants were largely eliminated between 2014 and 2022. What replaced them are incurrence tests — hurdles the borrower must clear only when it wants to do something specific. The borrower can operate at 8x leverage and never trip a covenant, as long as it does not incur new debt, pay dividends, or sell assets.
Before paying a dividend, making a distribution to the equity sponsor, or repurchasing shares, the borrower must satisfy a Fixed Charge Coverage Ratio (FCCR) test — typically 2.00x minimum. FCCR is defined as EBITDA minus capex minus taxes, divided by fixed charges (interest plus mandatory amortization). A general basket (often $25–50M or a percentage of Adjusted EBITDA) may allow smaller payments without testing.
The company may incur additional debt only if, on a pro forma basis after giving effect to the new debt, Total Net Leverage does not exceed the permitted ratio (e.g., 5.50x). This prevents layering on incremental debt when the balance sheet is already stressed. Side baskets — general, ratio-based, asset-backed — are extensively negotiated and can meaningfully expand borrowing capacity in cov-lite deals.
When the company sells an asset above a de minimis threshold (often $5–10M per transaction), it must either (a) reinvest the proceeds in the business within 12–18 months, or (b) prepay the term loan at par. A common split: 75% of net proceeds must be reinvested or used to prepay; the remaining 25% can be retained. In high yield bonds, this is called the "asset sale offer" provision and requires a tender offer at 101 cents.
The shift from maintenance to incurrence covenants began with the 2007–2008 pre-crisis deal boom, accelerated after 2010 as CLO demand for TLB paper intensified, and became effectively universal by 2014–2022. At the peak of the market (2021), over 90% of broadly syndicated term loans were issued with maintenance covenants applying only to the revolving credit facility — not the term loan.
The consequences became visible in 2022–2024 when rising rates and an economic slowdown pushed many overleveraged issuers into distress. Because these companies had no maintenance covenants, lenders had no early warning mechanism — the first signal was often a missed interest payment or a going-concern audit opinion, far later in the deterioration curve than a quarterly leverage test would have surfaced.
Direct lenders — BDCs, credit funds, unitranche providers — reacted by maintaining robust maintenance covenant packages. This is a key structural distinction between direct lending and the broadly syndicated market. When a direct lender says "we have maintenance covenants," they mean it. When a TLB arranges say "lightly covenanted," they usually mean incurrence-only with a springing maintenance test that activates only when the revolver is drawn more than 35–40%.
A covenant breach does not immediately mean lenders accelerate the loan. The process moves through well-defined steps, and experienced sponsors have playbooks for each one.
The moment the covenant test fails, the borrower is in technical default. This is not an Event of Default (EOD) in the traditional sense — it does not yet trigger acceleration or cross-defaults to other instruments. Most credit agreements provide a notification period (typically 5 business days from the compliance certificate date) during which the borrower must notify lenders of the breach.
The borrower approaches the administrative agent and requests a waiver or amendment. Required lender consent thresholds vary: minor amendments may need only Majority Lenders (more than 50% by commitment), while changes to economics, payment dates, or covenant definitions typically require all-lender consent or a supermajority (typically 66.7%). Timeline is 4–6 weeks from breach identification to executed amendment. Borrower pays an amendment fee — market is 25–50bps on outstanding principal — plus legal fees for lender counsel.
Most credit agreements — particularly in direct lending — include an equity cure right. The sponsor injects additional capital into the company, which is added to EBITDA (or used to repay debt) for the sole purpose of curing the covenant breach. Key mechanics:
Company breaches 5.50x maximum leverage at Q3 2025. Total Debt = $440M. LTM Adjusted EBITDA = $78.6M. Actual Leverage = 5.60x.
| Item | Value |
|---|---|
| Total Net Debt | $440.0M |
| LTM Adjusted EBITDA (as reported) | $78.6M |
| Actual Leverage | 5.60x |
| Covenant Maximum | 5.50x |
| EBITDA Required to Comply ($440M / 5.50x) | $80.0M |
| EBITDA Shortfall | $1.4M |
| Equity Cure Amount (= EBITDA Shortfall) | $1.4M |
The sponsor wires $1.4M into the business as an equity injection. This amount is added to LTM EBITDA solely for covenant testing purposes, bringing the test ratio to exactly 5.50x. Post-cure, the company is compliant. Note: the cash stays on the balance sheet and may reduce net debt in future periods, but for this quarter's test, only the EBITDA add is recognized.
If the lender agreement defines the cure against Gross Debt (rare), the sponsor could instead prepay $1.4M of the term loan to reduce the numerator. The economics are similar but the mechanics are different — confirm the cure definition before modeling.
If waiver negotiations break down — or if the breach is severe enough that lenders decide the business needs to be restructured rather than patched — lenders may enter a forbearance agreement. Under forbearance, lenders agree not to exercise their remedies (acceleration, enforcement on collateral) for a defined period (typically 30–90 days) while the borrower and sponsor develop a solution. Forbearance is not a cure; it is a pause. If no solution is found before the forbearance expires, lenders can declare an Event of Default and pursue remedies including acceleration.
Cov-lite does not mean the borrower can do anything it wants. Incurrence covenants still block the most value-destructive actions: taking on more debt, extracting equity through dividends, selling assets without applying proceeds to the loan. What cov-lite removes is the lender's early warning system. The business can deteriorate for 8 quarters, cross-default thresholds, and lenders have no trigger. What it protects against is phantom defaults — where a good business has a bad quarter, trips a maintenance test, and has to spend 6 weeks and $500K on an amendment that produces no economic change. The debate is whether false positives (unnecessary waivers) are more costly than false negatives (late-stage distress discovery). The direct lending market has answered: they still want maintenance covenants. The TLB market said: the cost of false positives is too high. Both views are defensible. Know the tradeoff cold.
A maintenance covenant is tested quarterly regardless of borrower actions — if the company underperforms, you know about it within 45 days of quarter-end. An incurrence covenant only triggers when the borrower takes a specific action (incur debt, pay dividends, sell assets). It matters to a direct lender because direct lending portfolios are concentrated — often 20–40 names versus 200+ in a broadly syndicated fund. You cannot afford passive monitoring. Maintenance covenants give you early warning, a negotiating seat at the table, and the ability to extract a fee, tighten documentation, or force operational changes before the situation becomes terminal.
First, you identify the cure amount: divide total debt by the covenant maximum to get the required EBITDA, then subtract reported EBITDA to find the shortfall. The sponsor injects that shortfall amount as equity into the borrower — it is added to LTM EBITDA solely for covenant testing that quarter. Key constraints: most agreements cap consecutive cures (no two quarters in a row), limit total cures over the loan life (often 3–5), and prohibit over-curing beyond the minimum needed. The sponsor does not get a "free EBITDA boost" — only the exact shortfall is permitted, and future-quarter step-downs are not affected.
You act now, not at breach. First, reforecast LTM EBITDA and debt for the next quarter end — a 4% revenue miss from consensus could push leverage to 5.5x, at which point you are at the old threshold but already violating the new 5.25x step-down. Second, engage the borrower and sponsor immediately: have the EBITDA bridge, the cure amount, and the amendment fee framework ready before the quarter closes. Third, check whether the credit agreement allows the step-down to be waived without all-lender consent (most do with majority lender approval). You want to be in amendment conversations 60 days before the potential breach, not 5 days after the compliance certificate is due.